We actively pursue new drug combination clinical trials for brain tumor patients. The newly developed Phase 0 platform combined with precision medicine allows us to understand pharmacodynamic endpoints in the tumor, providing insights for overcoming the brain-blood barrier and drug target inhibition. The newly established Ivy Pharmacodynamics Core is CLIA-certified where our assays and biosamples are validated and carefully monitored to provide trustworthy clinical quality results. Our long-term goal is to understand cellular and molecular mechanisms underlying glioma formation, thereby speeding current drug discovery processes for glioma treatment in patients.
Some of the ongoing projects are focused on addressing following:
- Biomarker and genomic analyses with next generation sequencing (IvySeq) to provide personalized enrollment recommendation.
- Pharmacodynamic analysis to assess treatment response and target modulation.
- Understanding resistance mechanisms of targeted inhibitors underlying disease progression.
An-Chi Tien, PhDPharmacodynamics Core Leader
Dr. An-Chi Tien received his Ph.D. from Baylor College of Medicine in Houston, Texas, before completing a postdoctoral fellowship in…